News Release

Corteva Reports Third-Quarter 2026 Results; Updates FY 2026 Outlook

- Third-quarter results reflect strong new product sales growth and continued operational excellence, helping mitigate broader market headwinds
- Pricing pressure was concentrated in North America and Latin America, reflecting an anticipated acetochlor headwind and competitive dynamics on molecules late in their lifecycle, respectively
- Full-year 2026 guidance updated reflecting weaker market conditions than previously anticipated in Brazil

INDIANAPOLIS, November 11, 2026 – Corteva, Inc. (NYSE: CTVA) ("Corteva" or the "Company") today reported financial results for the third quarter and nine months ended September 30, 2026.

3Q 2026 Results Overview

	Net Sales	Loss from Cont. Ops (After Tax)	EPS
Pro Forma GAAP	**$1.59B**	**$(54)M**	**$(0.08)**
vs. 3Q 2025	**(9)%**	**(190)%**	**(189)%**
	Organic[1] Sales	**Operating EBITDA[1]**	**Operating EPS[1]**
Adjusted Pro Forma NON-GAAP	**$1.58B**	**$0.22B**	**$0.06**
vs. 3Q 2025	**(9)%**	**(17)%**	**(57)%**

YTD 2026 Results Overview

	Net Sales	Inc. from Cont. Ops (After Tax)	EPS
Pro Forma GAAP	**$5.36B**	**$112M**	**$0.16**
vs. YTD 2025	**(1)%**	**(68)%**	**(68)%**
	Organic[1] Sales	**Operating EBITDA[1]**	**Operating EPS[1]**
Adjusted Pro Forma NON-GAAP	**$5.20B**	**$0.94B**	**$0.76**
vs. YTD 2025	**(4)%**	**Flat**	**49%**

2026 YTD Highlights

- Net sales decreased 1% and organic[1] sales decreased 4%. Volume was flat with growth in all regions, except Latin America. Price declined 4%, primarily reflecting pressure on molecules late in their lifecycle in Brazil and acetochlor in the U.S.
- Pro Forma GAAP income from continuing operations after taxes was $112 million, with a margin of 2.1%, while earnings per share (EPS) from continuing operations was $0.16 per share.
- Adjusted Pro Forma Operating EBITDA[1] and Operating EPS[1] were $943 million, and $0.76 per share, respectively. Adjusted Pro Forma Operating EBITDA margin expanded 30 basis points to 17.6%.
- Board of Directors authorized first common dividend post spin.
- Company updates full-year 2026 guidance[3] and expects Adjusted Pro Forma Operating EBITDA[1] to be in the range of $1.1 to $1.125 billion. Adjusted Pro Forma Operating EPS[1] is expected to be between $0.76 and $0.80 per share.

1. Organic Sales, Adjusted Pro Forma Operating EPS, and Adjusted Pro Forma Operating EBITDA are non-GAAP measures. See page 4 for further discussion. 2. North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa. 3. The Company does not provide the most comparable GAAP measure on a forward-looking basis. See page 3 for further discussion.

"We executed well against the things we can control. New products performed strongly, productivity delivered, and we generated broad-based organic growth outside Latin America. The pressure remains concentrated. Acetochlor pricing in the U.S. was consistent with our expectations, but Brazil was materially weaker than anticipated. While those conditions are reflected in our updated outlook, our strategy has not changed. Innovation, productivity and disciplined execution remain the foundation for sustainable long-term growth."

Luke Kissam
CEO

Summary of Third Quarter 2026

For the third quarter ended September 30, 2026, net sales decreased 9% versus the same period last year. Organic[1] sales decreased 9%.

Volume declined 2% year over year, as broad-based growth across most regions was more than offset by challenging market dynamics in Brazil. Pricing declined 7%, driven by competitive pressure on molecules late in their lifecycle in Brazil and U.S. acetochlor.

North America[2] reported 7% organic[1] sales growth, with volume up 19% as new product growth and early demand more than offset pricing headwinds in U.S. acetochlor.

EMEA[2] reported 14% organic[1] sales growth, driven by strong demand for new and differentiated products while holding price flat.

Latin America organic[1] sales declined 31%, reflecting challenging market dynamics in Brazil. Volumes decreased 24% due to elevated channel inventory and delayed purchasing given farmer liquidity constraints and high interest rates. Price declined 7% amid competitive pressure on mature molecules.

Asia Pacific reported 5% organic[1] sales growth, led by strong demand for new products, which supported 7% volume growth. Price declined 2% due to a competitive market environment.

Pro Forma GAAP income (loss) from continuing operations after income taxes was $(54) million in third quarter of 2026 compared to $60 million in third quarter of 2025, a margin decline of 680 basis points. Adjusted Pro Forma Operating EBITDA[1] for the third quarter of 2026 was $222 million, down 17% compared to prior year, translating into 140 basis points of Adjusted Pro Forma Operating EBITDA[1] margin erosion.

Adjusted Pro Forma ($ in millions, except where noted)	**3Q 2026**	**3Q 2025**	**% Change**	**% Organic[1] Change**
Net Sales	**$1,591**	**$1,742**	**(9)%**	**(9)%**
North America	$574	$537	7%	7%
EMEA	$239	$213	12%	14%
Latin America	$570	$791	(28)%	(31)%
Asia Pacific	$208	$201	3%	5%
3Q Operating EBITDA	**$222**	**$268**	**(17)%**	**N/A**

Adjusted Pro Forma ($ in millions, except where noted)	**YTD 2026**	**YTD 2025**	**% Change**	**% Organic[1] Change**
Net Sales	**$5,357**	**$5,419**	**(1)%**	**(4)%**
North America	$1,826	$1,821	-%	-%
EMEA	$1,438	$1,345	7%	1%
Latin America	$1,403	$1,601	(12)%	(18)%
Asia Pacific	$690	$652	6%	7%
YTD Operating EBITDA	**$943**	**$937**	**0%**	**N/A**

2026 Guidance

Agricultural fundamentals continue to be supported by the need for growers to improve productivity and protect yield, driving demand for differentiated technologies. However, Crop Protection market conditions have become more challenging, particularly in Brazil, where farmer liquidity constraints, elevated financing costs, just-in-time purchasing and increased pricing pressure have resulted in a significantly softer market than previously anticipated.

Demand for the Company's differentiated new products remains strong, and regional performance outside Latin America has been resilient.

Reflecting these market dynamics, primarily the deterioration in Brazil, the Company updated its full-year 2026 guidance[3]. Adjusted Pro Forma Operating EBITDA[1] is now expected to be between $1.1 billion and $1.125 billion, and Adjusted Pro Forma Operating EPS[1] is expected to be between $0.76 and $0.80 per share.

The Company remains focused on the priorities within its control, including differentiated innovation, productivity and disciplined execution.

The Company is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of its control, such as Significant Items, without unreasonable effort.

Third Quarter Conference Call

The Company will host a live webcast of its third quarter 2026 earnings conference call with investors to discuss its results and outlook tomorrow, November 12, 2026, at 10:30 a.m. ET. The slide presentation that accompanies the conference call is posted on the Company's Investor Events and Presentations page. A replay of the webcast will also be available on the Investor Events and Presentations page.

About Corteva

Corteva, Inc. (NYSE: CTVA) is a global crop protection company with a leading portfolio of differentiated solutions, including award-winning conventional chemistries and advantaged biologicals, seed-applied technologies and nature-inspired products that help farmers increase yields and protect crops from the stresses of weather, insects, weeds and diseases. Driven by a robust innovation pipeline, deep customer relationships, operational excellence, and disciplined capital allocation, Corteva is focused on creating value for our farmers, channel partners, employees, shareholders, and the communities in which it operates. More information can be found at www.corteva.com.

Cautionary Statement About Forward-Looking Statements

This press release contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "outlook," "will," "is designed to," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's (the "company's") financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; the anticipated benefits and impacts of Corteva's separation of its Seed business; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond the company's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the company's business, results of operations and financial condition. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of the company's products; (ii) failure to successfully develop and commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's technology and other agricultural products; (iv) failure to comply with competition and antitrust laws; (v) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of competition in the company's industry; (vii) risks related to recent funding and staff reductions at U.S. government agencies; (viii) effect of climate change and unpredictable seasonal and weather factors; (ix) effect of changes in agricultural and related policies of governments and international organizations; (x) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities; (xi) risk related to geopolitical and military conflict; (xii) effect of volatility in the company's input costs; (xiii) risks related to the company's global operations; (xiv) effect of industrial espionage and other disruptions to the company's supply chain, information technology or network systems; (xv) impact of the company's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xvi) failure of the company's customers to pay their debts to the company, including customer financing programs; (xvii) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xviii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to the company; (ix) increases in pension and other post-employment benefit plan funding obligations; (x) risks related to pandemics or epidemics; (xi) capital markets sentiment towards sustainability matters; (xxii) risk related to the company's intellectual property rights or defense against intellectual property claims asserted by others; (xxiii) the effect of counterfeit products; ((xxiv) risks related to Corteva's separation from DowDuPont; and (xxv) risks related to Corteva's separation of its Seed business including, but not limited to, whether the objectives of the separation will be achieved; the terms, structure, benefits and costs of any action or transaction resulting from the separation; risks related to Corteva and Vylor providing services to one another; the risk of any unexpected costs or expenses resulting from the separation and the risk of any litigation as a result of, or relating to, the separation, including but not limited to fraudulent conveyance claims.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled "Risk Factors" in Corteva's annual and quarterly reports filed on Forms 10-K and 10-Q with the U.S. Securities and Exchange Commission.

Regulation G (Non-GAAP Financial Measures)

This earnings release includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), adjusted pro forma operating EBITDA, adjusted pro forma operating earnings (loss) per share, and adjusted pro forma base income tax rate. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page A-4 of the Financial Statement Schedules.

Corteva is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as significant items, without unreasonable effort. For significant items reported in the periods presented, refer to page A-8 of the Financial Statement Schedules. The Company committed to restructuring activities to optimize the Crop Protection network of manufacturing and external partners, which are expected to be substantially complete in 2028. The Company expects to record approximately $130 million to $140 million net pre-tax restructuring charges during 2026 for these activities.

Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items.

Pro forma operating EBITDA is defined as pro forma earnings (loss) (i.e., pro forma income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items and separation costs. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites, as well as rental income recorded under the carve-out basis of accounting. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreements, between Corteva and Dow and/or DuPont, and between Corteva and Vylor, that are recorded by the Company as pre-tax income or expense. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility. Pro forma operating EBITDA margin is defined as pro forma operating EBITDA as a percentage of net sales. Adjusted pro forma operating EBITDA represents pro forma operating EBITDA, further adjusted to reflect management's estimates of certain incremental cost savings associated with operating Corteva as an independent public company that are not reflected in pro forma operating EBITDA. Adjusted pro forma operating EBITDA margin is defined as adjusted pro forma operating EBITDA as a percentage of net sales. Management believes this measure provides useful supplemental information regarding the expected cost structure of Corteva as an independent public company. The management adjustments are based on estimates and assumptions and actual costs and savings may differ materially from those reflected in the adjustments.

Pro forma operating earnings (loss) per share is defined as pro forma income (loss) per common share from continuing operations – diluted, excluding the after-tax impact of significant items, the after-tax impact of separation costs, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Corteva Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Adjusted pro forma operating earnings (loss) per share is defined as pro forma earnings (loss) per share plus the after-tax impact of management adjustments.

Pro forma adjusted base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), significant items, separation costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and non-operating (benefits) costs, plus the effect of management adjustments.

® TM Corteva Agriscience and its affiliated companies.

11/11/2026

Media Contact

Bethany Shively
+1 804-866-2377
bethany.shively@corteva.com

Investor Contact

Rafael Soares
+1 302-299-3418
rafael.soares@corteva.com

A-1
New Corteva
Pro Forma Combined Statements of Operations
(Dollars in millions, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
Net sales	**$ 1,591**	**$ 1,742**	**$ 5,357**	**$ 5,419**
Cost of goods sold	993	1,091	3,205	3,366
Research and development expense	131	112	346	328
Selling, general and administrative expenses	308	331	1,011	982
Amortization of intangibles	38	39	117	116
Restructuring and asset related charges - net	22	30	130	128
Separation costs	—	—	1	—
Other income (expense) - net	(8)	(2)	(106)	117
Interest expense	28	40	85	116
Income (loss) from continuing operations before income taxes	**63**	**97**	**356**	**500**
Provision for (benefit from) income taxes on continuing operations	117	37	244	153
Income (loss) from continuing operations after income taxes	**(54)**	**60**	**112**	**347**
Net income (loss) from continuing operations attributable to noncontrolling interests	2	2	7	7
Net income (loss) attributable to New Corteva	**$ (56)**	**$ 58**	**$ 105**	**$ 340**
Basic earnings (loss) per share of common stock:				
Basic earnings (loss) per share of common stock from continuing operations	$ (0.08)	$ 0.09	$ 0.16	$ 0.50
Diluted earnings (loss) per share of common stock:				
Diluted earnings (loss) per share of common stock from continuing operations	$ (0.08)	$ 0.09	$ 0.16	$ 0.50
Weighted average number of shares outstanding used in earnings (loss) per share (EPS) calculation (in millions)				
Basic	667.8	678.7	669.5	681.7
Diluted	667.8	680.2	670.7	683.1

A-2
New Corteva
Pro Forma Combined Balance Sheet
(Dollars in millions, except share amounts)

		September 30, 2026
Assets		
Current assets		
Cash and cash equivalents	$	1,798
Marketable securities		1
Accounts and notes receivable - net		4,106
Inventories		2,661
Other current assets		756
Total current assets		**9,322**
Investment in nonconsolidated affiliates		69
Property, plant and equipment		5,207
Less: Accumulated depreciation		3,478
Net property, plant and equipment		1,729
Goodwill		5,152
Other intangible assets		978
Deferred income taxes		694
Other assets		1,645
Total Assets	**$**	**19,589**
Liabilities and Equity		
Current liabilities		
Short-term borrowings	$	60
Accounts payable		2,514
Income taxes payable		94
Deferred revenue		67
Accrued and other current liabilities		1,316
Total current liabilities		**4,051**
Long-term debt		944
Other noncurrent liabilities		
Deferred income tax liabilities		57
Pension and other post-employment benefits		789
Other noncurrent obligations		1,628
Total noncurrent liabilities		**3,418**
Commitments and contingent liabilities		
Stockholders' equity		
Common stock, $0.01 par value		7
Additional paid-in capital		13,689
Retained earnings (accumulated deficit)		—
Accumulated other comprehensive income (loss)		(1,815)
Total New Corteva stockholders' equity		**11,881**
Noncontrolling interests		239
Total equity		12,120
Total Liabilities and Equity	**$**	**19,589**

A-3
New Corteva
Pro Forma Sales Information
(Dollars in millions, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
PRODUCT LINE NET SALES	**2026**	**2025**	**2026**	**2025**
Herbicides	$ 731	$ 813	$ 2,690	$ 2,668
Insecticides	396	409	1,172	1,181
Fungicides	171	222	768	868
Biologicals	115	147	271	328
Other	178	151	456	374
Net Sales	$ 1,591	$ 1,742	$ 5,357	$ 5,419

	Three Months Ended September 30,		Nine Months Ended September 30,	
GEOGRAPHIC NET SALES	**2026**	**2025**	**2026**	**2025**
North America [1]	$ 574	$ 537	$ 1,826	$ 1,821
EMEA [2]	239	213	1,438	1,345
Latin America	570	791	1,403	1,601
Asia Pacific	208	201	690	652
Net Sales	$ 1,591	$ 1,742	$ 5,357	$ 5,419

1. Reflects U.S. and Canada
2. Reflects Europe, Middle East and Africa

New Corteva
Pro Forma Reconciliation of Non-GAAP Measures
(Dollars in millions, except per share amounts)

	Three Months Ended September 30, 2026
Pro Forma Net Sales (GAAP)	$ 1,591
Add: Impacts from Currency and Portfolio / Other	(13)
Pro Forma Organic Sales (Non-GAAP)	$ 1,578

RECONCILIATION OF PRO FORMA INCOME (LOSS) FROM CONTINUING OPERATIONS AFTER INCOME TAXES TO ADJUSTED PRO FORMA OPERATING EBITDA	Three Months Ended September 30, 2026		Three Months Ended September 30, 2025	
	As Reported	Margin %	As Reported	Margin %
Pro forma income (loss) from continuing operations after income taxes (GAAP)	$ (54)	(3.4)%	$ 60	3.4 %
Pro forma provision for (benefit from) income taxes on continuing operations	117	7.4 %	37	2.1 %
Pro forma income (loss) from continuing operations before income taxes (GAAP)	63	4.0 %	97	5.6 %
Depreciation and amortization	105	6.6 %	105	6.0 %
Interest income	(17)	(1.1)%	(17)	(1.0)%
Interest expense	28	1.8 %	40	2.3 %
Exchange (gains) losses - net [1]	36	2.3 %	13	0.7 %
Non-operating (benefits) costs - net [2]	(10)	(0.6)%	5	0.3 %
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	(4)	(0.3)%	3	0.2 %
Significant items (benefit) charge [3]	21	1.3 %	30	1.7 %
Separation costs	—	— %	—	— %
Pro Forma Operating EBITDA (Non-GAAP) [5]	$ 222	14.0 %	$ 276	15.8 %
Management adjustments - net of depreciation expense [4]	—	— %	(8)	(0.5)%
Adjusted Pro Forma Operating EBITDA (Non-GAAP) [5]	$ 222	14.0 %	$ 268	15.4 %

1. Refer to page A-12 for pre-tax and after tax impacts of exchange (gains) losses.
2. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites, as well as rental income recorded under the carve-out basis of accounting. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont, and between Corteva and Vylor, that are recorded by the Company as pre-tax income or expense.
3. Refer to page A-8 for pre-tax and after tax impacts of significant items.
4. The New Corteva Combined Statements of Operations include all revenues and costs directly attributable to New Corteva, along with allocations of certain expenses for services from Corteva including but not limited to, general corporate expenses related to finance, legal, information technology, human resources, ethics and compliance, shared services, employee benefits and incentives, insurance and stock-based compensation. We received the benefit of economies of scale within Corteva's overall centralized model; however, in establishing these independent support functions, the expenses will generally be higher than the allocations applied in the Combined Statements of Operations. In developing these estimates, a detailed assessment was prepared of the resources and associated costs required to support the business after the spin-off. Estimated non-personnel third-party support costs were determined by estimating third-party spend in each function, and include the costs associated with outside services supporting executive management, finance, legal, information technology, employee benefits administration, treasury, risk management and procurement. From a timeframe standpoint, these additional costs materialized beginning in the third quarter of 2026 when organizational changes were made in preparation for the spin-off. Management believes the costs which were used as the basis for the management adjustments below are reasonable and representative of New Corteva's new cost base after the spin-off, and that the presentation of these adjustments is necessary to enhance an understanding of the pro forma effects of the spin-off.
5. The net sales amounts used to determine pro forma and adjusted pro forma operating EBITDA margin are $1,591 million and $1,742 million for the three months ended September 30, 2026 and 2025, respectively. Margin percentages may not foot, due to rounding.

New Corteva
Pro Forma Reconciliation of Non-GAAP Measures
(Dollars in millions, except per share amounts)

	Nine Months Ended September 30, 2026
Pro Forma Net Sales (GAAP)	$ 5,357
Add: Impacts from Currency and Portfolio / Other	(159)
Pro Forma Organic Sales (Non-GAAP)	$ 5,198

RECONCILIATION OF PRO FORMA INCOME (LOSS) FROM CONTINUING OPERATIONS AFTER INCOME TAXES TO ADJUSTED PRO FORMA OPERATING EBITDA	Nine Months Ended September 30, 2026		Nine Months Ended September 30, 2025	
	As Reported	**Margin %**	**As Reported**	**Margin %**
Pro forma income (loss) from continuing operations after income taxes (GAAP)	$ 112	2.1 %	$ 347	6.4 %
Pro forma provision for (benefit from) income taxes on continuing operations	244	4.6 %	153	2.8 %
Pro forma income (loss) from continuing operations before income taxes (GAAP)	356	6.6 %	500	9.2 %
Depreciation and amortization	316	5.9 %	312	5.8 %
Interest income	(58)	(1.1)%	(59)	(1.1)%
Interest expense	85	1.6 %	116	2.1 %
Exchange (gains) losses - net [1]	46	0.9 %	45	0.8 %
Non-operating (benefits) costs - net [2]	(40)	(0.7)%	6	0.1 %
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	4	0.1 %	27	0.5 %
Significant items (benefit) charge [3]	250	4.7 %	16	0.3 %
Separation costs	1	— %	—	— %
Pro Forma Operating EBITDA (Non-GAAP) [5]	$ 960	17.9 %	$ 963	17.8 %
Management adjustments - net of depreciation expense [4]	(17)	(0.3)%	(26)	(0.5)%
Adjusted Pro Forma Operating EBITDA (Non-GAAP) [5]	$ 943	17.6 %	$ 937	17.3 %

1. Refer to page A-12 for pre-tax and after tax impacts of exchange (gains) losses.
2. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites, as well as rental income recorded under the carve-out basis of accounting. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont, and between Corteva and Vylor, that are recorded by the Company as pre-tax income or expense.
3. Refer to page A-8 for pre-tax and after tax impacts of significant items.
4. The New Corteva Combined Statements of Operations include all revenues and costs directly attributable to New Corteva, along with allocations of certain expenses for services from Corteva including but not limited to, general corporate expenses related to finance, legal, information technology, human resources, ethics and compliance, shared services, employee benefits and incentives, insurance and stock-based compensation. We received the benefit of economies of scale within Corteva's overall centralized model; however, in establishing these independent support functions, the expenses will generally be higher than the allocations applied in the Combined Statements of Operations. In developing these estimates, a detailed assessment was prepared of the resources and associated costs required to support the business after the spin-off. Estimated non-personnel third-party support costs were determined by estimating third-party spend in each function, and include the costs associated with outside services supporting executive management, finance, legal, information technology, employee benefits administration, treasury, risk management and procurement. From a timeframe standpoint, these additional costs materialized beginning in the third quarter of 2026 when organizational changes were made in preparation for the spin-off. Management believes the costs which were used as the basis for the management adjustments below are reasonable and representative of New Corteva's new cost base after the spin-off, and that the presentation of these adjustments is necessary to enhance an understanding of the pro forma effects of the spin-off.
5. The net sales amounts used to determine pro forma and adjusted pro forma operating EBITDA margin are $5,357 million and $5,419 million for the nine months ended September 30, 2026 and 2025, respectively. Margin percentages may not foot, due to rounding.

New Corteva
Pro Forma Reconciliation of Non-GAAP Measures
(Dollars in millions, except per share amounts)

PRICE - VOLUME - CURRENCY ANALYSIS

REGION

	Q3 2026 vs. Q3 2025				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change [1] (Non-GAAP)		Price &			Portfolio /
	$	%	$	%	Product Mix	Volume	Currency	Other
North America	$ 37	7 %	$ 38	7 %	(12)%	19 %	— %	— %
EMEA	26	12 %	29	14 %	— %	14 %	(2)%	— %
Latin America	(221)	(28)%	(242)	(31)%	(7)%	(24)%	3 %	— %
Asia Pacific	7	3 %	11	5 %	(2)%	7 %	(2)%	— %
Total	$ (151)	(9)%	$ (164)	(9)%	(7)%	(2)%	— %	— %

PRODUCT LINE

	Q3 2026 vs. Q3 2025				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change [1] (Non-GAAP)		Price &			Portfolio /
	$	%	$	%	Product Mix	Volume	Currency	Other
Herbicides	$ (82)	(10)%	$ (87)	(11)%	(10)%	(1)%	1 %	— %
Insecticides	(13)	(3)%	(12)	(3)%	(3)%	— %	— %	— %
Fungicides	(51)	(23)%	(55)	(25)%	(9)%	(16)%	2 %	— %
Biologicals	(32)	(22)%	(36)	(24)%	(1)%	(23)%	2 %	— %
Other	27	18 %	26	17 %	(1)%	18 %	1 %	— %
Total	$ (151)	(9)%	$ (164)	(9)%	(7)%	(2)%	— %	— %

1. Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items.

New Corteva
Pro Forma Reconciliation of Non-GAAP Measures
(Dollars in millions, except per share amounts)

PRICE - VOLUME - CURRENCY ANALYSIS

REGION

	Nine Months 2026 vs. Nine Months 2025				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change [1] (Non-GAAP)		Price &			Portfolio /
	$	%	$	%	Product Mix	Volume	Currency	Other
North America	$ 5	— %	$ (2)	— %	(4)%	4 %	— %	— %
EMEA	93	7 %	20	1 %	(1)%	2 %	6 %	— %
Latin America	(198)	(12)%	(282)	(18)%	(9)%	(9)%	6 %	— %
Asia Pacific	38	6 %	43	7 %	(3)%	10 %	(1)%	— %
Total	$ (62)	(1)%	$ (221)	(4)%	(4)%	— %	3 %	— %

PRODUCT LINE

	Nine Months 2026 vs. Nine Months 2025				Percent Change Due To:			
	Net Sales Change (GAAP)		Organic Change [1] (Non-GAAP)		Price &			Portfolio /
	$	%	$	%	Product Mix	Volume	Currency	Other
Herbicides	$ 22	1 %	$ (61)	(2)%	(4)%	2 %	3 %	— %
Insecticides	(9)	(1)%	(26)	(2)%	(4)%	2 %	1 %	— %
Fungicides	(100)	(12)%	(137)	(16)%	(4)%	(12)%	4 %	— %
Biologicals	(57)	(17)%	(71)	(22)%	(4)%	(18)%	5 %	— %
Other	82	22 %	74	20 %	(7)%	27 %	2 %	— %
Total	$ (62)	(1)%	$ (221)	(4)%	(4)%	— %	3 %	— %

1. Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items.

New Corteva
Pro Forma Significant Items
(Dollars in millions, except per share amounts)

SIGNIFICANT ITEMS - PRE-TAX, AFTER TAX, AND EPS IMPACTS

	Pre-tax		After tax [7]		($ Per Share)	
	2026	2025	2026	2025	2026	2025
1st Quarter						
Restructuring and asset related charges - net [1]	$ (61)	$ (20)	$ (47)	$ (16)	$ (0.06)	$ (0.02)
Litigation settlement [2]	(85)	—	(64)	—	(0.10)	—
Income tax items [3]	—	—	—	55	—	0.08
1st Quarter – Total	$ (146)	$ (20)	$ (111)	$ 39	$ (0.16)	$ 0.06
2nd Quarter						
Restructuring and asset related charges - net [1]	$ (47)	$ (78)	$ (36)	$ (59)	$ (0.05)	$ (0.09)
Litigation settlement [2]	(36)	—	(27)	—	(0.04)	—
Gain (loss) on sale of assets [4]	—	14	—	12	—	0.02
Insurance proceeds [5]	—	98	—	74	—	0.11
2nd Quarter – Total	$ (83)	$ 34	$ (63)	$ 27	$ (0.09)	$ 0.04
3rd Quarter						
Restructuring and asset related charges, net [1]	$ (22)	$ (30)	$ (16)	$ (22)	$ (0.03)	$ (0.03)
Litigation settlement [2]	1	—	(8)	—	(0.01)	—
3rd Quarter – Total	$ (21)	$ (30)	$ (24)	$ (22)	$ (0.04)	$ (0.03)
Year-to-Date Total [6]	$ (250)	$ (16)	$ (198)	$ 44	$ (0.29)	$ 0.06

1. Third, second and first quarter 2026 include restructuring and asset related benefits (charges) of $(22), $(47), and $(61), respectively. The third and second quarter 2026 charges primarily related to the Crop Protection Operations Strategy Restructuring Program. The first quarter 2026 charges primarily consist of $(47) related to the 2026 Restructuring Actions and $(14) related to the Crop Protection Operations Strategy Restructuring Program.

   Third, second and first quarter 2025 include restructuring and asset related benefits (charges) of $(30), $(78) and $(20), respectively. The charges primarily related to the Crop Protection Operations Strategy Restructuring Program.
2. Third, second and first quarter 2026 includes estimated settlement charges associated with various lawsuits filed in connection with the Federal Trade Commission investigation.
3. First quarter 2025 reflects a deferred tax benefit of $55 associated with a change in a legal entity's U.S. tax characterization.
4. Second quarter 2025 includes a benefit of $14 related to the 2022 Restructuring Actions consisting of a gain on the sale of assets.
5. The insurance proceeds include proceeds received related to prior significant items.
6. Earnings per share for the year may not equal the sum of quarterly earnings per share due to the changes in average share calculations.
7. Unless specifically addressed in notes above, the income tax effect on significant items was calculated based upon the enacted tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment.

New Corteva
Pro Forma Reconciliation of Non-GAAP Measures
(Dollars in millions, except per share amounts)

Pro Forma Operating Earnings (Loss) Per Share (Non-GAAP)

Pro forma operating earnings (loss) per share is defined as pro forma earnings (loss) per common share from continuing operations – diluted, excluding the after-tax impact of significant items, the after-tax impact of separation costs, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Corteva Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Adjusted pro forma operating earnings (loss) per share is defined as pro forma operating earnings (loss) per share, including the after-tax impact of management adjustments.

	Three Months Ended September 30,			
	2026	2025	2026	2025
	$	*$*	*EPS (diluted)*	*EPS (diluted)*
Pro forma net income (loss) attributable to New Corteva (GAAP)	$ (56)	$ 58	$ (0.08)	$ 0.09
Less: Non-operating benefits (costs), after tax [1]	(57)	(4)	(0.08)	(0.01)
Less: Amortization of intangibles (existing as of Corteva Separation), after tax	(16)	(16)	(0.02)	(0.02)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax	3	(2)	—	—
Less: Significant items benefit (charge), after tax	(24)	(22)	(0.04)	(0.03)
Less: Separation costs, after tax	—	—	—	—
Pro Forma Operating Earnings (Loss) (Non-GAAP) [2]	$ 38	$ 102	$ 0.06	$ 0.15
Plus: Management adjustments, after tax [3]	—	(8)	—	(0.01)
Adjusted Pro Forma Operating Earnings (Loss) (Non-GAAP) [2]	$ 38	$ 94	$ 0.06	$ 0.14

	Nine Months Ended September 30,			
	2026	2025	2026	2025
	$	*$*	*EPS (diluted)*	*EPS (diluted)*
Pro forma net income (loss) attributable to New Corteva (GAAP)	$ 105	$ 340	$ 0.16	$ 0.50
Less: Non-operating benefits (costs), after tax [1]	(173)	(8)	(0.26)	(0.01)
Less: Amortization of intangibles (existing as of Corteva Separation), after tax	(47)	(47)	(0.07)	(0.06)
Less: Mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, after tax	(4)	(20)	(0.01)	(0.03)
Less: Significant items benefit (charge), after tax	(198)	44	(0.29)	0.06
Less: Separation costs, after tax	(1)	—	—	—
Pro Forma Operating Earnings (Loss) (Non-GAAP) [2]	$ 528	$ 371	$ 0.79	$ 0.54
Plus: Management adjustments, after tax [3]	(15)	(24)	(0.03)	(0.03)
Adjusted Pro Forma Operating Earnings (Loss) (Non-GAAP) [2]	$ 513	$ 347	$ 0.76	$ 0.51

1. Non-operating benefits (costs) consists of non-operating pension and other post-employment benefit (OPEB) credits (costs), tax indemnification adjustments and environmental remediation and legal costs associated with legacy businesses and sites, as well as rental income recorded under the carve-out basis of accounting. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont, and between Corteva and Vylor, that are recorded by the Company as pre-tax income or expense.
2. Refer to page A-10 for the Non-GAAP reconciliation of Pro Forma Operating EBITDA to Pro Forma Operating Earnings (Loss) per Share.
3. Refer to page A-5 for further discussion on management adjustments.

New Corteva

Adjusted Pro Forma Operating EBITDA to Adjusted Pro Forma Operating Earnings (Loss) Per Share

(Dollars in millions, except per share amounts)

Adjusted Pro Forma Operating EBITDA to Adjusted Pro Forma Operating Earnings (Loss) Per Share

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
Adjusted Pro Forma Operating EBITDA (Non-GAAP) [1,3]	$ 222	$ 268	$ 943	$ 937
Depreciation, including related to management adjustments [3]	(67)	(68)	(202)	(200)
Amortization of intangibles (post Corteva Separation)	(17)	(19)	(56)	(56)
Interest income	17	17	58	59
Interest expense	(28)	(40)	(85)	(116)
Adjusted pro forma (provision for) benefit from income taxes on continuing operations before significant items, separation costs, non-operating benefits (costs), amortization of intangibles (existing as of Corteva Separation), mark-to-market gains (losses) on certain foreign currency contracts not designated as hedges, and exchange gains (losses) **(Non-GAAP)** [1]	(56)	(48)	(97)	(202)
Exchange gains (losses), after tax [2]	(31)	(14)	(41)	(68)
Net (income) loss attributable to non-controlling interests	(2)	(2)	(7)	(7)
Adjusted Pro Forma Operating Earnings (Loss) (Non-GAAP) [1, 3]	$ 38	$ 94	$ 513	$ 347
Diluted Shares (in millions)	667.8	680.2	670.7	683.1
Adjusted Pro Forma Operating Earnings (Loss) Per Share (Non-GAAP) [1, 3]	$ 0.06	$ 0.14	$ 0.76	$ 0.51

1. Refer to pages A-4 - A-7 and A-9 for Non-GAAP reconciliations.
2. Refer to page A-12 for pre-tax and after tax impacts of exchange gains (losses).
3. Refer to page A-5 for further discussion on management adjustments.

New Corteva
Pro Forma Reconciliation of Non-GAAP Measures
(Dollars in millions)

Reconciliation of Pro Forma Effective Income Tax Rate to Adjusted Pro Forma Base Income Tax Rate

Pro forma base income tax rate is defined as the pro forma effective income tax rate less the effect of exchange gains (losses), significant items, separation costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and non-operating (benefits) costs. Adjusted pro forma base income tax rate is the pro forma base income tax rate, including the effect of management adjustments.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	2025	2026	2025
Pro forma income (loss) from continuing operations before income taxes **(GAAP)**	$ 63	$ 97	$ 356	$ 500
Add: Significant items (benefit) charge [1]	21	30	250	16
Separation costs	—	—	1	—
Non-operating (benefits) costs	(10)	5	(40)	6
Amortization of intangibles (existing as of Corteva Separation)	21	20	61	60
Mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	(4)	3	4	27
Less: Exchange gains (losses) [2]	(36)	(13)	(46)	(45)
Pro forma income (loss) from continuing operations before income taxes, significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) **(Non-GAAP)**	$ 127	$ 168	$ 678	$ 654
Add: Management adjustments [3]	—	(10)	(20)	(30)
Adjusted pro forma income (loss) from continuing operations before income taxes, significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) **(Non-GAAP)**	$ 127	$ 158	$ 658	$ 624
Pro forma provision for (benefit from) income taxes on continuing operations **(GAAP)**	$ 117	$ 37	$ 244	$ 153
Add: Tax (expenses) benefits on significant items (benefit) charge [1]	(3)	8	52	60
Tax benefits on separation costs	—	—	—	—
Tax (expenses) benefits on non-operating (benefits) costs	(67)	1	(213)	(2)
Tax benefits on amortization of intangibles (existing as of Corteva Separation)	5	4	14	13
Tax (expenses) benefits on mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	(1)	1	—	7
Tax (expenses) benefits on exchange gains (losses) [2]	5	(1)	5	(23)
Pro forma provision for (benefit from) income taxes on continuing operations before significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) **(Non-GAAP)**	$ 56	$ 50	$ 102	$ 208
Add: Tax benefits (expenses) on management adjustments, after tax [3]	—	(2)	(5)	(6)
Adjusted pro forma provision for (benefit from) income taxes on continuing operations before significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and exchange gains (losses) **(Non-GAAP)**	$ 56	$ 48	$ 97	$ 202
Pro forma effective income tax rate **(GAAP)**	185.7 %	38.1 %	68.5 %	30.6 %
Significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges effect	(129.7)%	(5.2)%	(53.2)%	7.3 %
Tax rate from continuing operations before significant items, separation costs, non-operating (benefits) costs, amortization of intangibles (existing as of Corteva Separation), and mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges	56.0 %	32.9 %	15.3 %	37.9 %
Exchange gains (losses), net effect [2]	(11.9)%	(3.1)%	(0.3)%	(6.1)%
Pro Forma Base Income Tax Rate From Continuing Operations (Non-GAAP)	44.1 %	29.8 %	15.0 %	31.8 %
Management adjustments, net effect [3]	— %	0.6 %	(0.3)%	0.6 %
Adjusted Pro Forma Base Income Tax Rate From Continuing Operations (Non-GAAP)	44.1 %	30.4 %	14.7 %	32.4 %

1. See page A-8 for further detail on the significant items table.
2. See page A-12 for further details of exchange gains (losses).
3. Refer to page A-5 for further discussion on management adjustments.

Exchange Gains/Losses

The Company routinely uses foreign currency exchange contracts to offset its net exposures, by currency, related to the foreign currency-denominated monetary assets and liabilities. The objective of this program is to maintain an approximately balanced position in foreign currencies in order to minimize, on an after-tax basis, the effects of exchange rate changes on net monetary asset positions. The hedging program gains (losses) are largely taxable (tax deductible) in the United States (U.S.), whereas the offsetting exchange gains (losses) on the remeasurement of the net monetary asset positions are often not taxable (tax deductible) in their local jurisdictions. The net pre-tax exchange gains (losses) are recorded in other income (expense) - net and the related tax impact is recorded in provision for (benefit from) income taxes on continuing operations in the Consolidated Statements of Operations.

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	2025	2026	2025
Subsidiary Monetary Position Gain (Loss)				
Pre-tax exchange gain (loss)	$ (18)	$ 24	$ 77	$ (101)
Local tax (expenses) benefits	1	(11)	(24)	(11)
Net after-tax impact from subsidiary exchange gain (loss)	$ (17)	$ 13	$ 53	$ (112)
Hedging Program Gain (Loss)				
Pre-tax exchange gain (loss)	$ (18)	$ (37)	$ (123)	$ 56
Tax (expenses) benefits	4	10	29	(12)
Net after-tax impact from hedging program exchange gain (loss)	$ (14)	$ (27)	$ (94)	$ 44
Total Exchange Gain (Loss)				
Pre-tax exchange gain (loss)	$ (36)	$ (13)	$ (46)	$ (45)
Tax (expenses) benefits	5	(1)	5	(23)
Net after-tax exchange gain (loss)	$ (31)	$ (14)	$ (41)	$ (68)

As shown above, the "Total Exchange Gain (Loss)" is the sum of the "Subsidiary Monetary Position Gain (Loss)" and the "Hedging Program Gain (Loss)."

Corteva, Inc.
Consolidated Statements of Operations
(Dollars in millions, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2026	**2025**	**2026**	**2025**
Net sales	**$ 2,458**	**$ 2,618**	**$ 13,742**	**$ 13,491**
Cost of goods sold	1,534	1,644	6,624	6,918
Research and development expense	397	351	1,126	1,061
Selling, general and administrative expenses	732	725	2,773	2,632
Amortization of intangibles	159	162	513	485
Restructuring and asset related charges - net	17	30	158	131
Separation costs	99	7	230	7
Other income (expense) - net	(34)	(23)	(266)	95
Interest expense	75	46	158	134
Income (loss) from continuing operations before income taxes	**(589)**	**(370)**	**1,894**	**2,218**
Provision for (benefit from) income taxes on continuing operations	(62)	(62)	479	477
Income (loss) from continuing operations after income taxes	**(527)**	**(308)**	**1,415**	**1,741**
Income (loss) from discontinued operations after income taxes	(41)	(10)	(95)	(87)
Net income (loss)	**(568)**	**(318)**	**1,320**	**1,654**
Net income (loss) attributable to noncontrolling interests	2	2	9	8
Net income (loss) attributable to Corteva	**$ (570)**	**$ (320)**	**$ 1,311**	**$ 1,646**
Basic earnings (loss) per share of common stock:				
Basic earnings (loss) per share of common stock from continuing operations	$ (0.79)	$ (0.46)	$ 2.10	$ 2.54
Basic earnings (loss) per share of common stock from discontinued operations	(0.06)	(0.01)	(0.14)	(0.13)
Basic earnings (loss) per share of common stock	**$ (0.85)**	**$ (0.47)**	**$ 1.96**	**$ 2.41**
Diluted earnings (loss) per share of common stock:				
Diluted earnings (loss) per share of common stock from continuing operations	$ (0.79)	$ (0.46)	$ 2.10	$ 2.54
Diluted earnings (loss) per share of common stock from discontinued operations	(0.06)	(0.01)	(0.14)	(0.13)
Diluted earnings (loss) per share of common stock	**$ (0.85)**	**$ (0.47)**	**$ 1.96**	**$ 2.41**
Average number of shares outstanding used in earnings (loss) per share (EPS) calculation (in millions)				
Basic	667.8	678.7	669.5	681.7
Diluted	667.8	678.7	670.7	683.1

Corteva, Inc.
Consolidated Balance Sheets
(Dollars in millions, except per share amounts)

	September 30, 2026	December 31, 2025	September 30, 2025
Assets			
Current assets			
Cash and cash equivalents	$ 3,932	$ 4,521	$ 2,509
Marketable securities	1	9	77
Accounts and notes receivable - net	7,491	6,371	7,784
Inventories	5,482	5,667	5,310
Other current assets	980	767	758
Total current assets	**17,886**	**17,335**	**16,438**
Investment in nonconsolidated affiliates	147	160	141
Property, plant and equipment	9,840	9,551	9,633
Less: Accumulated depreciation	5,657	5,331	5,431
Net property, plant and equipment	4,183	4,220	4,202
Goodwill	10,416	10,465	10,512
Other intangible assets	7,845	8,301	8,428
Deferred income taxes	335	320	434
Other assets	2,219	2,044	2,043
Total Assets	**$ 43,031**	**$ 42,845**	**$ 42,198**
Liabilities and Equity			
Current liabilities			
Short-term borrowings	$ 3,988	$ 894	$ 2,685
Accounts payable	4,431	4,398	4,337
Income taxes payable	146	155	254
Deferred revenue	440	3,579	483
Accrued and other current liabilities	2,445	3,099	2,661
Total current liabilities	**11,450**	**12,125**	**10,420**
Long-term debt	3,458	1,686	1,688
Other noncurrent liabilities			
Deferred income tax liabilities	567	251	373
Pension and other post-employment benefits	877	2,434	2,215
Other noncurrent obligations	1,942	1,963	2,041
Total noncurrent liabilities	**6,844**	**6,334**	**6,317**
Commitments and contingent liabilities			
Stockholders' equity			
Common stock, $0.01 par value; 1,666,666,667 shares authorized; issued at September 30, 2026 - 667,304,000; December 31, 2025 - 672,163,000; and September 30, 2025 - 676,755,000	7	7	7
Additional paid-in capital	26,934	27,001	27,039
Retained earnings (accumulated deficit)	533	(67)	834
Accumulated other comprehensive income (loss)	(2,981)	(2,797)	(2,661)
Total Corteva stockholders' equity	**24,493**	**24,144**	**25,219**
Noncontrolling interests	244	242	242
Total equity	24,737	24,386	25,461
Total Liabilities and Equity	**$ 43,031**	**$ 42,845**	**$ 42,198**

Corteva, Inc.
Consolidated Statements of Cash Flows
(Dollars in millions, except per share amounts)

	Nine Months Ended September 30,	
	2026	**2025**
Operating activities		
Net income (loss)	$ 1,320	$ 1,654
(Income) loss from discontinued operations after income taxes	95	87
Adjustments to reconcile net income (loss) to cash provided by (used for) operating activities:		
Depreciation and amortization	942	897
Provision for (benefit from) deferred income tax	280	(72)
Net periodic pension and OPEB (benefit) cost, net	(7)	27
Pension and OPEB contributions	(1,567)	(110)
Net (gain) loss on sales of property, businesses, consolidated companies and investments	3	(17)
Restructuring and asset related charges - net	158	131
Other net loss	441	386
Changes in assets and liabilities, net		
Accounts and notes receivable	(1,372)	(1,659)
Inventories	163	331
Accounts payable	(47)	123
Deferred revenue	(3,130)	(2,824)
Other assets and liabilities	(1,157)	105
Cash provided by (used for) operating activities - continuing operations	(3,878)	(941)
Cash provided by (used for) operating activities - discontinued operations	(70)	(28)
Cash provided by (used for) operating activities	(3,948)	(969)
Investing activities		
Capital expenditures	(354)	(369)
Proceeds from sales of property, businesses and consolidated companies - net of cash divested	10	26
Acquisitions of businesses - net of cash acquired	(43)	—
Investments in and loans to nonconsolidated affiliates	(7)	(7)
Proceeds from sales and maturities of investments	8	68
Proceeds from (payment for) settlement of net investment hedge	—	(56)
Other investing activities, net	(4)	(17)
Cash provided by (used for) investing activities	(390)	(355)
Financing activities		
Net change in borrowings (less than 90 days)	3,264	1,119
Proceeds from debt	2,660	1,643
Payments on debt	(1,059)	(1,116)
Repurchase of common stock	(500)	(770)
Proceeds from exercise of stock options	38	75
Dividends paid to stockholders	(361)	(354)
Other financing activities, net	(53)	(43)
Cash provided by (used for) financing activities	3,989	554
Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents	(27)	85
Increase (decrease) in cash, cash equivalents and restricted cash equivalents	(376)	(685)
Cash, cash equivalents and restricted cash equivalents at beginning of period	4,725	3,422
Cash, cash equivalents and restricted cash equivalents at end of period	$ 4,349	$ 2,737